Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection

Bevirimat [3-O-(3′,3′-dimethylsuccinyl)betulinic acid] is the first in a new class of anti-human immunodeficiency virus (HIV) drugs that inhibit viral maturation by specifically blocking cleavage of the Gag capsid (CA) precursor, CA-SP1, to mature CA protein, resulting in defective core condensation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Smith, Patrick F., Ogundele, Abayomi, Forrest, Alan, Wilton, John, Salzwedel, Karl, Doto, Judy, Allaway, Graham P., Martin, David E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2007
Assuntos:
Clinical Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2043264/
https://ncbi.nlm.nih.gov/pubmed/17638699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00152-07
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados